CCKAR — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ce-326597 (SCHEMBL44599)	1.00	19/20
SCHEMBL502712	1.00	16/20
SCHEMBL502739	1.00	16/20
SCHEMBL502146	1.00	15/20
SCHEMBL502229	1.00	15/20
SCHEMBL502707	1.00	15/20
Devazepide (SCHEMBL148766)	1.00	13/20
SCHEMBL194796	0.65	12/20
SCHEMBL184846	0.59	12/20
Sincalide (SCHEMBL122365)	1.00	11/20
Ceruletide (SCHEMBL122757)	0.66	10/20
Tepoxalin (SCHEMBL75441)	0.64	10/20
SCHEMBL431477	0.45	10/20
SCHEMBL433024	0.44	10/20
Ceruletide (SCHEMBL511740)	0.62	9/20
Ceruletide (SCHEMBL29520)	0.69	8/20
SCHEMBL453867	0.59	8/20
SCHEMBL73258	0.38	8/20
SCHEMBL433742	0.40	7/20
SCHEMBL84897	0.64	5/20

Clinical trials — most relevant to CCKAR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes	PHASE4	UNKNOWN
Behavioral Mechanism of Energy Compensation With Exercise	PHASE3	COMPLETED
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36	PHASE1/PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans	PHASE1	COMPLETED
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC	PHASE1	COMPLETED
Effect of GSK962040 on Oesophageal Function	PHASE1	COMPLETED
Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia	nan	COMPLETED
Enteroendocrine Cells Before and After Sleeve Gastrectomy	nan	COMPLETED
Investigation of Acute Physiological Effects of Aspiration Therapy	nan	COMPLETED
Regulation of Fat-stimulated Neurotensin Secretion in Healthy Subjects	nan	COMPLETED
CCK1R Function in Patient Leukocytes	nan	COMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
Route of Nutritional Support for Pancreatic Fistula	nan	UNKNOWN
SANICS II Trial: Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition	nan	COMPLETED
Nutritional Management of Acute and Chronic Enterocutaneous Fistulae	nan	UNKNOWN
Bile Acid-induced GLP-secretion. A Study in Cholecystectomized Subjects	nan	COMPLETED
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC	nan	RECRUITING
Effects of Lipids on Gastric Emptying, Satiety Hormones, and Appetite in Severe Overweight	nan	COMPLETED
-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.	nan	COMPLETED
Eating Behaviour in Crohn's Disease	nan	COMPLETED
The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Multifaceted Analysis of the Adaptation of Rowers in the Process of Sports Training	nan	COMPLETED
The Role of Estradiol and Progesterone on Appetite Regulation and Energy Balance	nan	RECRUITING
Effects on Remission of Type 2 Diabetes Mellitus Following Gastric Bypass Alone vs Gastric Bypass Combined With Truncal Vagotomy	nan	RECRUITING
Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss	nan	COMPLETED
Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CCKAR binder may also engage these)

Protein	Name	Similarity
O08786	—	1.000	O08786 →
P30551	—	1.000	P30551 →
O97772	—	0.999	O97772 →
Q63931	—	0.997	Q63931 →
Q5D0K2	—	0.994	Q5D0K2 →
P70031	—	0.987	P70031 →
Q9WTV9	—	0.964	Q9WTV9 →
P47751	—	0.963	P47751 →
Q9WTV8	—	0.963	Q9WTV8 →
O62809	—	0.963	O62809 →
P97295	—	0.960	P97295 →
Q49LX5	—	0.960	Q49LX5 →
P79113	—	0.960	P79113 →
Q9DDN6	—	0.958	Q9DDN6 →
SSTR1	Somatostatin receptor type 1	0.957	landscape →
P30560	—	0.956	P30560 →
O02836	—	0.956	O02836 →
Q9TUP7	—	0.956	Q9TUP7 →
NPY2R	Neuropeptide Y receptor type 2	0.956	landscape →
Q9GK74	—	0.955	Q9GK74 →
P28646	—	0.955	P28646 →
HCRTR2	Orexin receptor type 2	0.955	landscape →
Q5IS62	—	0.955	Q5IS62 →
Q91559	—	0.954	Q91559 →
Q62463	—	0.954	Q62463 →
O97661	—	0.953	O97661 →
AVPR1A	Vasopressin V1a receptor	0.953	landscape →
P58308	—	0.953	P58308 →
HCRTR1	Orexin/Hypocretin receptor type 1	0.952	landscape →
Q63447	—	0.952	Q63447 →